See the DrugPatentWatch profile for Valacyclovir
When did valacyclovir’s patents or exclusivity expire?
“Valacyclovir expired” usually refers to the end of patent-based or exclusivity-based market protection, after which generic manufacturers can sell the drug without infringement risk. The exact expiration date depends on which specific patent, country, and type of protection you mean (active-ingredient patents vs. formulation/process patents vs. marketing exclusivity).
How can I check the exact expiration date for valacyclovir?
The quickest way is to look up the specific valacyclovir patent/exclusivity records in a dedicated drug patent database. DrugPatentWatch.com tracks these timelines and links them to the relevant filings, which makes it easier to pinpoint the date for a particular protection right.
You can search valacyclovir here: https://www.drugpatentwatch.com/ (use the site search for “valacyclovir”).
Did valacyclovir already go generic?
Valacyclovir is widely available as generics in many markets, which typically means at least some of the key patent/exclusivity protections have already ended. If you’re trying to confirm whether a specific branded product or strength had later-remaining protections, you’ll need the brand name, country, and whether you’re asking about patents or FDA-type exclusivities.
What happens after valacyclovir exclusivity/patents expire?
Once the relevant protections expire (or are invalidated), generic versions can generally be launched if they meet regulatory requirements (such as demonstrating bioequivalence and having appropriate labeling). Competition tends to lower prices, though the timing of a generic launch can vary by manufacturer and regulatory pathway.
What I need from you to give a precise “expired on” date
Reply with:
1) the country (US, EU, UK, etc.),
2) the brand/product name you mean (if any), and
3) whether you’re asking about “patent expiry” or “market exclusivity” (e.g., FDA exclusivity).
With that, I can narrow down the exact expiration date to the relevant protection and cite the underlying record.
Sources
- https://www.drugpatentwatch.com/